Abstract
The COVID-19 pandemic has continued to evolve with the emergence of new variants, each presenting unique challenges and implications for public health. This article provides an overview of the most recent variants, including JN.1, HV.1, FLiRT, and Pangolin Coronavirus GX-P2V (short_3UTR), alongside notable older variants such as BA.2, BA.2.86 (Pirola), XBB (Kraken), and EG.5 (Eris). A risk assessment highlights the varying impacts of these variants and new onset of KP1.1, KP.2, KP.3 and KP3.1 particularly during the summer surge of cases and underscores the importance of monitoring and adapting public health strategies. The article examines symptoms, diagnostic methods, and treatment options, noting that while the severity of the disease has generally decreased, the rise of new variants necessitates ongoing vigilance. Effective prevention remains crucial, supported by continued research and adaptation of health measures. It highlights the variability in symptom presentation among individuals, including the occurrence of asymptomatic cases. The analysis underscores the importance of monitoring symptoms closely and undergoing testing for accurate diagnosis and management. The findings emphasize the need for updated vaccines, flexible treatment protocols, and a comprehensive approach to managing the evolving COVID-19 landscape. The findings underscore the importance of ongoing research, vaccination, and flexible treatment protocols in mitigating the impact of COVID-19 on global health.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call